Trial Profile
Phase IIa trial of diphencyprone in patients with cutaneous metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2019
Price :
$35
*
At a glance
- Drugs Diphencyprone (Primary)
- Indications Cancer metastases; Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors Hapten Pharmaceuticals
- 07 Jan 2015 New trial record
- 19 Dec 2014 This trial is underway, according to a RXi Pharmaceuticals media release.